This is a small, early-stage R&D collaboration for a mega-cap biotech — no near-term revenue or earnings impact. Monitor for future milestone announcements or clinical data readouts on AHC candidates, but no immediate trading catalyst.
Price Chart
Executive Summary
Regeneron announced a strategic research collaboration with Parabilis Medicines to discover Antibody-Helicon Conjugates (AHCs) targeting previously undruggable intracellular proteins. Regeneron will pay Parabilis $125M upfront ($50M cash + $75M equity commitment), with up to ~$2.2B in additional milestone payments plus tiered royalties. The deal is a modest R&D bet for a $73B biotech — the upfront is ~0.17% of market cap — but opens a novel therapeutic modality.
Key Financial Metrics
Key Facts
- Regeneron pays $125M to Parabilis: $50M upfront + $75M equity commitment
- Up to ~$2.2B in total milestone payments plus tiered royalties up to low double-digits
- Collaboration focuses on Antibody-Helicon Conjugates (AHCs) for intracellular targets
- Five initial targets with option to add more upon additional option payments
- Regeneron responsible for development, manufacturing, and worldwide commercialization
Financial Impact
Upfront cost of $125M (~0.17% of REGN's $73.2B market cap); total deal value up to ~$2.2B in milestones, but these are contingent and distant
Risk Factors
- Helicon platform is unproven in humans; AHCs are a novel modality with high technical risk
- Milestone payments are contingent on development success — most early-stage collaborations never reach commercialization
- No change to Regeneron's core revenue drivers (Eylea, Dupixent, Libtayo)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3296473 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 1d ago | ANALYST-UPGRADE | — | awaiting T+20 | — | — |
Sep 3, 2026 29d ago | Insider Cluster | $843.47 $735.20 | ▼ −12.84% | ▼ −11.65% | $735.20 (−12.84%) |
Aug 24, 2026 5w ago | Court Ruling | $828.50 $803.90 | ▼ −2.97% | ▼ −4.28% | $735.20 (−11.26%) |
Aug 20, 2026 6w ago | Press Release | $826.64 $784.85 | ▼ −5.06% | ▼ −5.06% | $735.20 (−11.06%) |
Aug 12, 2026 7w ago | Insider Cluster | $797.99 $793.26 | ▼ −0.59% | ▲ +1.30% | $735.20 (−7.87%) |
Aug 11, 2026 7w ago | Court Ruling | $797.00 $807.65 | ▲ +1.34% | ▲ +2.40% | $735.20 (−7.75%) |
Jul 30, 2026 9w ago | 8-K | $738.34 $807.71 | ▲ +9.40% | ▲ +5.43% | $735.20 (−0.43%) |
Jul 30, 2026 9w ago | Press Release | $738.34 $807.71 | ▲ +9.40% | ▲ +5.43% | $735.20 (−0.43%) |
Jul 27, 2026 9w ago | Press Release | $695.18 $833.56 | ▼ −19.91% | ▼ −16.52% | $735.20 (−5.76%) |
Jul 17, 2026 11w ago | Press Release | $676.69 $800.70 | ▲ +18.33% | ▲ +13.88% | $735.20 (+8.65%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access